Phase 1, open label, multiple dose escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of CP 751,871 in patients with advanced solid tumors.
Phase of Trial: Phase I
Latest Information Update: 11 Sep 2014
At a glance
- Drugs Figitumumab (Primary)
- Indications Ewing's sarcoma; Solid tumours
- Focus Adverse reactions
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Jan 2012 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.